Knowledge is our power. Science is our tool.

Mr. Asadorian has been the Chief Financial Officer of AcelRx Pharmaceuticals, a NASDAQ-listed, specialty pharmaceutical company since August 2017. Mr. Asadorian has over 30 years of experience in finance, including 15 years’ experience as a CFO with biotech and life sciences companies including Amyris and Barr Pharmaceuticals . Prior to that, Mr. Asadorian was a Partner in the Transaction Services Group of PwC, LLP in New York. Mr. Asadorian holds an MBA in Finance from the University of Manchester and a B. Sc., Business Administration in Accounting from Xavier University in Cincinnati. Mr. Asadorian is a Certified Public Accountant (inactive, Ohio).

Mr. Foreman has over 20 years of professional experience in private equity, corporate finance, and financial technology. Mr. Foreman is currently a Partner and the Chief Investment Officer of Tuatara Capital, L.P. Prior to co-founding Tuatara Al was a Managing Director at Highbridge Principal Strategies, and earlier was a Managing Director at J.P. Morgan in the Financial Sponsors Group and Private Equity Fund Services business. Previously, Al held executive roles at Vitech Systems Group and Virtual Growth, and he began his career at Citigroup. Mr. Foreman earned a B.S. in Finance from the University of Connecticut and a dual J.D./MBA from Arizona State University.

Mr. Archibald is an independent businessman; President of Cypress Energy Corp., a private investment company, since March 2008.  Mr. Archibald also serves on the board and various committees of Palisade Capital, Panorama Mountain Resort, Petronas Energy Canada, Spartan Delta Corp., Serafina Energy Ltd., and Willow Biosciences.  He has been involved in the formation of numerous companies as well as serving in an executive and director capacity in a number of private and public companies as well as not for profit entities.  He currently also serves on the board of Winsport.   Mr Archibald has an MBA from the Ivey Business School and a BComm. from the University of Alberta.

With more than 30 years experience, Dr. Jim Lalonde has led highly performing biotech R&D teams at Altus Biologics, Codexis and Inscripta.  As R&D lead at Codexis, his team develop the best-in-class CodeEvolver® Protein Engineering technology combining machine learning, protein modeling, HTP expression, and assay and NGS to create enzymes for biocatalysis, oral enzyme replacement therapies, nutrition, and diagnostics. His team developed and commercialized processes to more than 25 pharmaceutical actives, including blockbusters such as Lipitor®, Januvia®, and Paxlovid® and were recognized with three U.S. Presidential Green Chemistry Awards.  He now applies his experience as a scientific advisory to several start-ups.  Jim has a PhD in Organic Chemistry from Texas A&M University and an Honours BSc from Lakehead University.

Dr. Savile has 17 years’ experience in science, commercial, and operations roles in biotech. He is a highly experienced scientist and operations expert focused on the scale up and commercialization of biobased processes for pharma, food & beverage, and energy. Dr. Savile has acted as technical leader and commercial program manager on several large R&D programs that led to commercial processes (see, for example: Science 2010, 329, 305-309, U.S. Patent 8,293,507, PNAS 2014, 111, 16436-16441, U.S. Patent 8,288,141). In addition, Dr. Savile has published more than 25 articles, book chapters, and patents related to development of biobased process with a focus on transformative chemistries and difficult- to-synthesize products. Prior to Willow, Dr. Savile worked at Codexis, Zymergen, and Intrexon. He received his PhD in Organic Chemistry from McGill University in 2005.